MUCOSAL ABETA VACCINATION; MODULATING THE IMMUNE RESPONSE

粘膜 ABETA 疫苗接种；

• 批准号: 7349532
• 负责人: CYNTHIA A LEMERE
• 金额: $ 3.5万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7349532
• 关键词: MUCOSAL; ABETA; VACCINATION; MODULATING; IMMUNE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Abeta immunotherapy has potential for preventing and possibly treating Alzheimer¿s disease (AD) in humans. Studies in genetically-engineered AD mouse models have consistently demonstrated efficacy of the Abeta vaccine both in lowering CNS Abeta and improving cognition without any adverse effects. However, the first human clinical trial was halted due to meningoencephalitis in approximately 6% of patients; recognition of the full-length Abeta immunogen as a self-protein may have attributed to these adverse events. Non-human primates, including Caribbean vervets (Chlorocebus aethiops), have the same amyloid precursor protein (APP) and Abeta as humans, and have age-related cerebral plaque deposition. Thus, they may serve as a better animal model for studying Abeta clearance and immune responses to Abeta vaccination. We are training vervets for behavioral testing of cognitive functions and will begin Abeta vaccination in the next several months. Our goals are to characterize the humoral and cellular immune responses to a novel Abeta vaccine and to determine the vaccine¿s efficacy in lowering Abeta within the nervous system and improving cognition.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一，该子项目和研究者 (PI) 可能已从其他 NIH 来源获得主要资助，因此可以在其他 CRISP 机构中得到体现。列出的是该中心，该中心不一定是研究人员的机构，Abeta 免疫疗法具有预防和可能治疗阿尔茨海默病的潜力。对人类 AD 小鼠模型的研究一致证明 Abeta 疫苗在降低中枢神经系统 Abeta 和改善认知方面均有效，且没有任何不良影响。大约 6% 的患者；将全长 Abeta 免疫原识别为自身蛋白可能归因于这些不良事件，包括加勒比马獾 (Chlorocebus)。 aethiops）与人类具有相同的淀粉样前体蛋白（APP）和Abeta，并且具有与年龄相关的脑斑块沉积，因此，它们可以作为研究Abeta清除和对Abeta疫苗接种的免疫反应的更好的动物模型。我们的目标是表征对新型 Abeta 疫苗的体液和细胞免疫反应，并确定疫苗。其在降低神经系统内的 Abeta 和改善认知方面的功效。